vs
null（EDIT）与RECURSION PHARMACEUTICALS, INC.（RXRX）财务数据对比。点击上方公司名可切换其他公司
RECURSION PHARMACEUTICALS, INC.的季度营收约是null的1.4倍（$35.5M vs $24.7M），null净利率更高（-22.7% vs -304.2%，领先281.5%），RECURSION PHARMACEUTICALS, INC.同比增速更快（681.7% vs -19.2%），null自由现金流更多（$-36.4M vs $-47.3M），过去两年null的营收复合增速更高（366.9% vs 60.5%）
Editas Medicine是一家处于临床阶段的生物技术企业，总部位于马萨诸塞州剑桥市，在科罗拉多州博尔德市也设有研发场地，目前公司依托CRISPR基因编辑技术，开发针对罕见疾病的治疗方案。
Recursion Pharmaceuticals是一家临床阶段生物技术企业，依托人工智能技术和高通量生物实验体系，开发针对罕见病、肿瘤、炎症性疾病等领域未满足医疗需求的创新疗法，核心市场覆盖北美，与全球多家生物制药企业合作推进在研管线落地。
EDIT vs RXRX — 直观对比
营收规模更大
RXRX
是对方的1.4倍
$24.7M
营收增速更快
RXRX
高出700.9%
-19.2%
净利率更高
EDIT
高出281.5%
-304.2%
自由现金流更多
EDIT
多$10.9M
$-47.3M
两年增速更快
EDIT
近两年复合增速
60.5%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $24.7M | $35.5M |
| 净利润 | $-5.6M | $-108.1M |
| 毛利率 | — | 59.8% |
| 营业利润率 | -31.3% | -304.8% |
| 净利率 | -22.7% | -304.2% |
| 营收同比 | -19.2% | 681.7% |
| 净利润同比 | 87.6% | 39.6% |
| 每股收益（稀释后） | $0.03 | $-0.17 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EDITRXRX
| Q4 25 | $24.7M | $35.5M | ||
| Q3 25 | $7.5M | $5.2M | ||
| Q2 25 | $3.6M | $19.2M | ||
| Q1 25 | $4.7M | $14.7M | ||
| Q4 24 | $30.6M | $4.5M | ||
| Q3 24 | $61.0K | $26.1M | ||
| Q2 24 | $513.0K | $14.4M | ||
| Q1 24 | $1.1M | $13.8M |
净利润EDITRXRX
| Q4 25 | $-5.6M | $-108.1M | ||
| Q3 25 | $-25.1M | $-162.3M | ||
| Q2 25 | $-53.2M | $-171.9M | ||
| Q1 25 | $-76.1M | $-202.5M | ||
| Q4 24 | $-45.4M | $-178.9M | ||
| Q3 24 | $-62.1M | $-95.8M | ||
| Q2 24 | $-67.6M | $-97.5M | ||
| Q1 24 | $-62.0M | $-91.4M |
毛利率EDITRXRX
| Q4 25 | — | 59.8% | ||
| Q3 25 | — | -183.8% | ||
| Q2 25 | — | -4.9% | ||
| Q1 25 | — | -48.0% | ||
| Q4 24 | — | -181.4% | ||
| Q3 24 | — | 53.7% | ||
| Q2 24 | — | 36.2% | ||
| Q1 24 | — | 19.1% |
营业利润率EDITRXRX
| Q4 25 | -31.3% | -304.8% | ||
| Q3 25 | -325.4% | -3327.6% | ||
| Q2 25 | -1440.6% | -916.8% | ||
| Q1 25 | -1635.1% | -1297.9% | ||
| Q4 24 | -152.2% | -4042.4% | ||
| Q3 24 | -107649.2% | -377.1% | ||
| Q2 24 | -14016.2% | -697.4% | ||
| Q1 24 | -5902.3% | -698.4% |
净利率EDITRXRX
| Q4 25 | -22.7% | -304.2% | ||
| Q3 25 | -333.0% | -3135.3% | ||
| Q2 25 | -1487.8% | -894.2% | ||
| Q1 25 | -1633.5% | -1373.3% | ||
| Q4 24 | -148.3% | -3935.5% | ||
| Q3 24 | -101870.5% | -367.5% | ||
| Q2 24 | -13178.8% | -676.6% | ||
| Q1 24 | -5458.1% | -662.4% |
每股收益（稀释后）EDITRXRX
| Q4 25 | $0.03 | $-0.17 | ||
| Q3 25 | $-0.28 | $-0.36 | ||
| Q2 25 | $-0.63 | $-0.41 | ||
| Q1 25 | $-0.92 | $-0.50 | ||
| Q4 24 | $-0.55 | $-0.56 | ||
| Q3 24 | $-0.75 | $-0.34 | ||
| Q2 24 | $-0.82 | $-0.40 | ||
| Q1 24 | $-0.76 | $-0.39 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $146.6M | $743.3M |
| 总债务越低越好 | — | $9.6M |
| 股东权益账面价值 | $27.3M | $1.1B |
| 总资产 | $186.5M | $1.5B |
| 负债/权益比越低杠杆越低 | — | 0.01× |
8季度趋势，按日历期对齐
现金及短期投资EDITRXRX
| Q4 25 | $146.6M | $743.3M | ||
| Q3 25 | $165.6M | $659.8M | ||
| Q2 25 | $178.5M | $525.1M | ||
| Q1 25 | $221.0M | $500.5M | ||
| Q4 24 | $269.9M | $594.4M | ||
| Q3 24 | $265.1M | $427.6M | ||
| Q2 24 | $279.1M | $474.3M | ||
| Q1 24 | $296.2M | $296.3M |
总债务EDITRXRX
| Q4 25 | — | $9.6M | ||
| Q3 25 | — | $11.9M | ||
| Q2 25 | — | $14.2M | ||
| Q1 25 | — | $16.4M | ||
| Q4 24 | $57.4M | $19.0M | ||
| Q3 24 | — | $20.5M | ||
| Q2 24 | — | $22.9M | ||
| Q1 24 | — | — |
股东权益EDITRXRX
| Q4 25 | $27.3M | $1.1B | ||
| Q3 25 | $13.5M | $1.0B | ||
| Q2 25 | $19.2M | $919.1M | ||
| Q1 25 | $62.4M | $933.9M | ||
| Q4 24 | $134.3M | $1.0B | ||
| Q3 24 | $175.6M | $524.6M | ||
| Q2 24 | $232.0M | $584.4M | ||
| Q1 24 | $294.4M | $401.2M |
总资产EDITRXRX
| Q4 25 | $186.5M | $1.5B | ||
| Q3 25 | $201.8M | $1.4B | ||
| Q2 25 | $210.6M | $1.3B | ||
| Q1 25 | $263.7M | $1.3B | ||
| Q4 24 | $341.6M | $1.4B | ||
| Q3 24 | $327.6M | $726.5M | ||
| Q2 24 | $384.8M | $775.9M | ||
| Q1 24 | $440.3M | $557.8M |
负债/权益比EDITRXRX
| Q4 25 | — | 0.01× | ||
| Q3 25 | — | 0.01× | ||
| Q2 25 | — | 0.02× | ||
| Q1 25 | — | 0.02× | ||
| Q4 24 | 0.43× | 0.02× | ||
| Q3 24 | — | 0.04× | ||
| Q2 24 | — | 0.04× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-36.4M | $-46.1M |
| 自由现金流经营现金流 - 资本支出 | $-36.4M | $-47.3M |
| 自由现金流率自由现金流/营收 | -147.3% | -133.1% |
| 资本支出强度资本支出/营收 | 0.2% | 3.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-378.3M |
8季度趋势，按日历期对齐
经营现金流EDITRXRX
| Q4 25 | $-36.4M | $-46.1M | ||
| Q3 25 | $-30.8M | $-117.4M | ||
| Q2 25 | $-50.2M | $-76.4M | ||
| Q1 25 | $-47.8M | $-132.0M | ||
| Q4 24 | $-50.8M | $-115.4M | ||
| Q3 24 | $-52.6M | $-59.2M | ||
| Q2 24 | $-57.1M | $-82.2M | ||
| Q1 24 | $-49.9M | $-102.3M |
自由现金流EDITRXRX
| Q4 25 | $-36.4M | $-47.3M | ||
| Q3 25 | $-31.3M | $-117.6M | ||
| Q2 25 | — | $-79.6M | ||
| Q1 25 | $-47.9M | $-133.8M | ||
| Q4 24 | $-51.3M | $-116.7M | ||
| Q3 24 | $-55.5M | $-63.8M | ||
| Q2 24 | $-60.6M | $-83.4M | ||
| Q1 24 | $-51.7M | $-109.0M |
自由现金流率EDITRXRX
| Q4 25 | -147.3% | -133.1% | ||
| Q3 25 | -414.6% | -2272.5% | ||
| Q2 25 | — | -413.9% | ||
| Q1 25 | -1028.6% | -907.4% | ||
| Q4 24 | -167.6% | -2567.7% | ||
| Q3 24 | -90998.4% | -244.6% | ||
| Q2 24 | -11804.3% | -578.5% | ||
| Q1 24 | -4558.9% | -789.9% |
资本支出强度EDITRXRX
| Q4 25 | 0.2% | 3.5% | ||
| Q3 25 | 5.7% | 4.7% | ||
| Q2 25 | 0.0% | 16.4% | ||
| Q1 25 | 2.4% | 12.4% | ||
| Q4 24 | 1.8% | 28.6% | ||
| Q3 24 | 4788.5% | 17.5% | ||
| Q2 24 | 681.1% | 8.2% | ||
| Q1 24 | 164.8% | 48.2% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
